ンゲンラ皮下注射剤特別調査

基本情報

NCT ID

NCT05602766

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

1

治験依頼者名

Pfizer

概要

The purpose of this study is to learn about the long-term safety and effects of Ngenla. Ngenla is approved for treatment of GHD (Growth hormone deficiency) without epiphyseal closure under daily medical practice. Registration criteria of this study are the patients who: * Have GHD without epiphyseal closure and receiving Ngenla for the first time. * Are boys less than 15 years or girls less than 13 years of age at the start of treatment with Ngenla. All patients in this study will receive Ngenla according to the prescriptions. We will examine their experiences for a long time. This will help us to determine the safety and effects of Ngelna for long-term use. Patients will be followed up from the date of first Ngenla treatment until November 30, 2027.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)